| November 2025 |
Horizon Europe |
Possible association to Horizon Europe: Request for information |
Department of Industry, Science and Resources |
| October 2025 |
National Health and Medical Research Strategy |
Draft National Health and Medical Research Strategy consultation |
Department of Health, Disability and Ageing |
| September 2025 |
Strategic Examination of R&D (SERD) |
AusBiotech response to consultation on Issues Papers |
Department of Industry, Science and Resources |
| September 2025 |
Australian Centre for Disease Control Bill 2025 |
AusBiotech Submission to the Community Affairs Legislation Committee |
Community Affairs Legislation Committee |
| July 2025 |
Economic Reform Roundtable submission |
AusBiotech and Medicines Australia submission to Economic Reform Roundtable |
Federal Treasury |
| April 2025 |
Strategic Examination of R&D |
AusBiotech Submission to Strategic Examination of R&D |
Department of Industry, Science and Resources |
| 31 January 2025 |
Federal Budget |
Pre-Budget Submission 2025-26: AusBiotech and MTPConnect
|
Federal Treasury |
| 31 January 2025 |
Federal Budget |
Pre-Budget Submission 2025-26: AusBiotech and Medicines Australia – Australian Life Sciences Council |
Federal Treasury |
| 31 January 2025 |
Federal Budget |
Pre-Budget Submission 2025-26: Cell and Gene Catalyst |
Federal Treasury |
| 31 January 2025 |
Federal Budget |
Pre-Budget Submission 2025-26: AusBiotech, Medical Technology Association of Australia and Medicines Australia – National One Stop Shop |
Federal Treasury |
| 02 April 2024 |
NSW Innovation Blueprint |
AusBiotech submission in response to the NSW Innovation Blueprint – Discussion Paper |
Investment NSW |
| 23 February 2024 |
HTA |
Cell & Gene Catalyst submission in response to the Health Technology Assessment Policy and Methods Review - Consultation 2 |
Department of Health and Aged Care |
| 23 February 2024 |
Fees & Charges |
AusBiotech submission in response to the TGA fees and charges proposal 2024-25 consultation paper |
Therapeutic Goods Administration |
| 25 January 2024 |
Clinical trials |
The Research & Development Taskforce's National One Stop Shop Pre 2024-25 Federal Budget Submission |
The Treasury |
| 16 October 2023 |
Cell & gene therapies |
Australia's Cell & Gene Catalyst's response to the Unleashing the Potential of our Healthcare Workforce – Scope of practice review |
Department of Health and Aged Care |
| 16 October 2023 |
RNA technologies |
AusBiotech's response to the Understanding our RNA potential: discussion paper |
Department of Industry, Science and Resources |
| 8 September 2023 |
Regulation |
AusBiotech submission in response to Draft guidance on requirements for Class 4 in-house IVDs used for screening faecal microbiota transplant (FMT) donors |
Therapeutic Goods Administration |
| 15 August 2023 |
Prostheses List |
AusBiotech submission in response to the Prostheses List Reforms Consultation Paper 7 - Proposed measures for compliance, assurance and information sharing |
Department of Health |
| 28 July 2023 |
SME support |
AusBiotech's submission in response to the Industry Growth Program |
Department of Industry, Science and Resources |
| 14 July 2023 |
Funding |
AusBiotech's submission in response to Improving alignment and coordination between the Medical Research Future Fund and NHMRC’s Medical Research Endowment Account |
Department of Health and Aged Care |
| 16 March 2023 |
Fees & Charges |
AusBiotech's submission in response to the TGA Fees and Charges Proposal 2023-2024 consultation paper |
Therapeutic Goods Administration |
| 9 February 2023 |
Understanding and complying with advertising rules for therapeutic goods |
AusBiotech's submission in response to draft guidance for therapeutic goods advertising and ASX announcements |
Therapeutic Goods Administration |
| 3 February 2023 |
Manufacturing |
AusBiotech's submission in response to the National Reconstruction Fund consultation paper |
Department of Industry, Science and Resources |
| 27 January 2023 |
TGA Funding |
AusBiotech's joint submission for Securing sustainable funding for the Therapeutic Goods Administration |
The Treasury |
| 27 January 2023 |
Regulation |
AusBiotech's response to the 'TGA Learn' consultation
|
Therapeutic Goods Administration |
| 26 September 2022 |
Regulation |
AusBiotech's joint submission to the TGA's proposed regulatory changes for clinical trials for medical devices |
Therapeutic Goods Administration |
| 25 March 2022 |
Regulation |
AusBiotech's response to Priority Review Pathway for Biologicals: feasibility, potential eligibility criteria and determination process |
Therapeutic Goods Administration |
| 4 March 2022 |
TGA's Fees and charges |
AusBiotech's response to the TGA's Fees and charges 2022 - 2023 proposal
|
Therapeutic Goods Administration |
| 25 February 2022 |
Prostheses List |
AusBiotech submission in response to the Prostheses List Reforms - Consultation Paper No. 3 - A modernised fit-for-purpose listing process |
Department of Health |
| 17 February 2022 |
R&D Tax Incentive |
AusBiotech's submission in response to the Draft Industry Research and Development (R&D Tax Incentive on clinical trials, Phase 0, I, II, III for an unapproved therapeutic good) Determination 2021 |
Department of Industry, Science, Energy and Resources |
| 1 December 2021 |
Manufacturing cell and gene therapies |
Presenting to the Inquiry into the Australian Manufacturing Industry: AusBiotech's speech is available on Hansard, and Further Questions on Notice are available here.
|
Economics References Committee |
| 15 October 2021 |
Commercialisation |
AusBiotech's joint response to the Higher Education Research Commercialisation (HERC) IP Framework. |
Department of Education, Skills and Employment |
| 10 September 2021 |
Manufacturing cell and gene therapies |
AusBiotech's joint submission to the Economics References Committee’s Inquiry into the Australian Manufacturing Industry |
Economics References Committee |
| 16 August 2021 |
Patent Box |
AusBiotech's response to the Australian Patent Box: Treasury Discussion Paper on Policy Design. |
Treasury |
| 9 April 2021 |
Commercialisation |
AusBiotech's response to the Department’s University Research Commercialisation consultation paper |
Department of Education, Skills and Employment |
| 17 March 2021 |
Gene technology
|
AusBiotech's response to the Department of Health's consultation on: Modernising and future-proofing the National Gene Technology Scheme |
Department of Health |
| 15 February 2021 |
Prostheses List |
AusBiotech's response to the Department of Health's Consultation Paper: Options for reforms and improvements to the Prostheses List |
Department of Health |
